Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Biospectal Announces Two Independent Global Health Research and Validation Studies Using Biospectal OptiBP™ Blood Pressure Measurement App

Biospectal, the remote patient monitoring and biosensing software company, today announced the next step in its commitment to global health by launching two independent research and validation studies using Biospectal OptiBP™.

Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal’s OptiBP smartphone app and data platform integration with the WHO’s Digital Antenatal Care module, following WHO SMART guidelines and built on the WHO Open Smart Register Platform (OpenSRP).

The two new independent global health research and validation studies follow the recent publication of a large-scale, third-party research study in Scientific Reports in Nature, which demonstrated Biospectal’s ability to measure blood pressure as accurately as a sphygmomanometer, commonly referred to as a standard blood pressure cuff. Both new studies further Biospectal’s ability to transform the global network of smartphones into a connected, clinical-grade blood pressure monitoring platform — democratizing access and bringing the power of remote patient monitoring to people and communities worldwide.

Funded by the Bill & Melinda Gates Foundation, the first independent study is underway in three countries — South Africa, Tanzania and Bangladesh — and is concentrated on routine blood pressure measurement and monitoring as well as hypertension disorders during pregnancy.

The second independent study in Indonesia is being conducted with the Summit Institute for Development (SID) in collaboration with Ona Kenya Limited and is funded through Grand Challenges Canada’s Saving Lives at Birth initiative, with additional backing from USAID, the Bill & Melinda Gates Foundation, Norwegian Agency for Development Cooperation (NORAD), the Korean International Cooperation Agency (KOICA) and the HRP Special Programme of Research, Development and Research Training in Human Reproduction.

The study centers on hypertension disorders during pregnancy, including chronic hypertension, preeclampsia-eclampsia, preeclampsia superimposed on chronic hypertension and gestational hypertension. Findings from the two studies will be available in the first half of 2022.

Biospectal OptiBP enables anyone in the world with a smartphone to turn their device into a connected, clinical-grade blood pressure monitor in the time it takes to download and install an app. The OptiBP medical-grade smartphone app uses a smartphone camera’s lens to easily measure and record a user’s blood pressure flow via their fingertip. Using proprietary algorithms and optical signal capture methods, Biospectal OptiBP then transforms the captured data into blood pressure values in approximately 20 seconds — half the time of a typical blood pressure cuff. The captured blood pressure data connects seamlessly with a user’s clinicians to support treatment regimens that help improve health, longevity and quality of life. View a short video of how Biospectal OptiBP works here.

“The ability for anyone to assess blood pressure accurately with a readily available device such as a smartphone opens the door to personal monitoring of many acute and chronic medical conditions. It’s a massive leap forward in technology toward empowerment for wellness, and crucial in the post Covid-19 world,” said Dr. Anuraj Shankar of University of Oxford, U.K., and Lead Investigator for Community Health at the Eijkman-Oxford Clinical Research Unit, and the Summit Institute for Development in Indonesia. “The synergy with other point-of-care tests and the transition to digital health globally means optimal care for pregnant women experiencing hypertension, and will lead to more healthy mothers and healthy babies.”

Hypertension is a global threat and is the leading cause of death worldwide, according to the WHO. Fewer than one in five of the estimated 1.13 billion people with hypertension have it under control, and two-thirds live in low- and middle-income countries. Hypertension prevalence rates are on the rise in developing countries with no improvement in awareness or control rates.

As the only pure software solution on the market in an easy to use smartphone app, Biospectal is the answer to the major problem of monitoring and measuring blood pressure in developing countries. “For low and middle-income countries around the globe, this type of technology is a game-changer in the fight against non-communicable diseases, dominated by hypertension and cardiovascular disease,” says Professor Alain Labrique, Director of the Johns Hopkins Global mHealth Initiative and Associate Chair for Research in International Health. “For the billions of people living in remote, rural communities, having access to accurate blood pressure readings will enable early diagnosis and hopefully, treatment — preventing illness and loss of life.”

“Smartphones are the number one device worldwide and someone in Tanzania or Indonesia is more likely to have a smartphone than any other consumer device. Biospectal’s pure software and app approach simultaneously democratizes access to blood pressure measurement and monitoring due to the widespread worldwide availability of smartphones,” said Biospectal CEO and co-founder, Eliott Jones. “We can scale our modern, medical-grade, easy-to-use blood pressure measurement and monitoring OptiBP technology globally with extreme efficiency to any country, at any time.”

Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is planned for public beta launch in the second half of 2021.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy